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and 40,573.33/cure, respectively. ICER was -$44,974.88/cure favoring daptomycin.
Results from the one-way sensitivity analysis showed that duration of vancomycin 
intravenous treatment, cost of hospital night stay, and duration of daptomycin intra-
venous treatment were inﬂ uential on the ICER; however, no break-even points were 
established and the model remained robust. Probabilistic sensitivity analysis displayed 
77.9% of the ICER distribution in the dominant quadrant. Acceptability curve showed 
that daptomycin was q88.6% cost-effective compared to vancomycin at all ICER
ranges. CONCLUSIONS: Daptomycin was cost-effective compared to vancomycin
due to decreased total direct cost and reduction in inpatient stay. As a result, the pro-
portion of ICER in the probabilistic sensitivity analysis favored daptomycin 77.9%
which was reﬂ ected in the acceptability curve.
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OBJECTIVES: The ritonavir-boosted protease inhibitor (PI/r) darunavir (darunavir/r)
800/100 mg QD has recently been licensed in the US for use in treatment-naïve 
HIV-infected adults. The objective of this study was to compare the cost and efﬁ cacy 
of darunavir/r-based triple therapy with other combination therapies using PI/rs 
currently licensed for this patient population in the US. METHODS: Virologic efﬁ cacy 
was measured by the percentage of individuals with plasma HIV RNA  50 copies/mL 
(the current goal of antiretroviral therapy) at 48 weeks, based on a systematic review
of clinical trials of PI/r-based regimens in treatment-naïve populations. One-year 
antiretroviral therapy costs were calculated in 2008 US dollars. The base-case analysis 
considered PI/rs with a tenofovir-based backbone regimen; an abacavir-based back-
bone was considered in scenario analysis. RESULTS: The base-case analysis showed
that darunavir/r was the most efﬁ cacious PI/r, with an incremental cost-efﬁ cacy 
ratio (ICER) of $31,524 per additional individual with virologic response, when 
compared with fosamprenavir/r, the only other point on the efﬁ ciency frontier of 
PI/r-based initial therapy. All other PI/rs were less efﬁ cacious and more costly than 
darunavir/r or fosamprenavir/r, including the two most commonly prescribed: atazana-
vir/r and lopinavir/r. Before the introduction of darunavir/r, atazanavir/r was most
efﬁ cacious but with a higher ICER of $46,612 compared with fosamprenavir/r.
Darunavir/r has an average cost of $25,059 per individual with virologic response, 
compared with $25,880 and $26,526 for atazanavir/r and lopinavir/r, respectively. 
Given a ﬁ xed budget of $10 million, darunavir/r successfully treats 399 individuals,
compared with 386 and 377 for atazanavir/r and lopinavir/r, respectively. Similar
results were obtained in scenario analysis using an abacavir-based backbone. CON-
CLUSIONS: Darunavir/r 800/100 mg QD has a lower cost per individual with viro-
logic response after 48 weeks than the 2 most commonly prescribed PI/rs in 
treatment-naïve, HIV-infected adults and provides more beneﬁ t per additional cost 
than other currently available PI/rs.
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OBJECTIVES: To assess the cost-effectiveness of Truvada versus Combivir and Kivexa
in the treatment of antiretroviral naïve HIV-1 infected patients in Mexico. METHODS:
A Markov model was developed to assess the incremental cost effectiveness of Truvada
vs Combivir and Kivexa. Clinical data was derived from published clinical trials (Study 
903 and CNA30024) and other secondary sources to create a model of disease pro-
gression and treatment patterns. Both health care and treatment costs were considered.
The analysis was performed from the Mexican Health Care System perspective; costs 
were reported in 2008 US dollar. Costs and health outcomes were discounted at 5%.
A second-order probabilistic Monte Carlo sensitivity analysis was conducted to assess 
the effects of parameter uncertainty on the study ﬁ ndings. RESULTS: The model 
projects an accumulated discounted cost to the Mexican health care system per patient 
receiving the Truvada regimen of US$28,776 compared to US$24,605 for the Kivexa
regimen and US$22,999 for the Combivir regimen. The accumulated discounted effect
is 5.85 QALYs per patient receiving Truvada compared to 4.89 QALYs for Kivexa
and 4.81 QALYs for Combivir. This results in an incremental cost for Truvada and
Kivexa vs. Combivir of US$5,805 per QALY and US$ 19,436 per QALY respectively. 
Considering a willingness to pay (WTP) threshold of US$10,000 per QALY there is a
90% probability that treatment with Truvada is cost-effective relative to Combivir
CONCLUSIONS: Results from these analyses suggest that in the Mexican setting, use
of Truvada in place of standard Combivir and Kivexa for treatment of HIV is likely
to be cost effective. These conclusions are supported by conservative assumptions and
sensitivity analyses.
PIN15
COMPARING COST-EFFECTIVENESS OF THE THREE- VERSUS TWO-DOSE
VACCINATION PROTOCOL AGAINST HEPATITIS B IN ADOLESCENTS
Hajarizadeh B1, Rashidian A1, Haghdoost AA2, Alavian SM3
1Tehran University of Medical Sciences, Tehran, Tehran, Iran, 2Kerman University of Medical 
Sciences, Kerman, Kerman, Iran, 3Baqyatallah Research Center for Gastroenterology and Liver 
Diseases, Tehran, Tehran, Iran
OBJECTIVES: A three-dose regimen is the usual protocol for hepatitis-B vaccination. 
An alternate two-dose vaccination schedule has been recently approved for adoles-
cents. This study was conducted to compare cost-effectiveness of three- versus two-
dose hepatitis-B vaccination regimen in adolescents. METHODS: We applied health 
care provider perspectivein this study. To measure vaccination coverage and costs, we 
retrieved the data of hepatitis-B mass vaccination campaign run in 2007 covering 
1989-born adolescents in Iran. Vaccines immunogenicity were derived from literature.
The cost variables considered included recurrent costs, personnel costs, publicity costs, 
transportation costs, and overhead costs. The required data to estimate recurrent, 
national-level supervision, and publicity costs were provided from existing data and 
interview with experts. To estimate vaccine administration, provincial supervision, and
outreach costs, the data were provided from some provinces and projected to the
country. We used WHO recommended proportions to estimate transportation and 
overhead costs. RESULTS: Total cost for a three-dose campaign was estimated as $2.3
per-dose-administered. The same cost for two-dose campaign would be $2.1 per-dose-
administered. Total cost of a three-dose campaign, in the best scenario was $7.1 per-
person-seroprotected and would be $5.5-$9.4 in alternative scenarios according to 
sensitivity analysis. The same cost for a two-dose campaign, in the best scenario was
$4.5 per-person-seroprotected and would be $3.6-$8.7 in alternative scenarios. To 
immunize one more person in a 3-dose protocol compared to a 2-dose protocol, $58.6 
would be spent by health system. This cost would be $9.6-$155.3 in various scenarios. 
In addition, in some scenarios two-dose protocol might have deﬁ nite priority to three-
dose protocol because of both higher effectiveness and lower cost. CONCLUSIONS:
Running a two-dose protocol HBV vaccination campaign in adolescents instead of 
current three-dose protocol campaign is more cost-effective. Conducting an analysis 
with societal perspective which includes vaccinee costs, two-dose protocol will be more 
advantageous.
PIN16
COST-EFFECTIVENESS ANALYSIS OF POSACONAZOLE FOR
PROPHYLAXIS IN PATIENTS WITH NEUTROPENIA IN SOUTH KOREA
Kim Y1, Lee D2, Jun S3, Jo C4, Lee S3, Kim B1
1Seoul National University, Seoul, South Korea, 2Catholic University, Seoul, South Korea, 
3Korea Institute of Environment and Health, Seoul, South Korea, 4Hallym University, 
Chuncheon, South Korea
OBJECTIVES: This study aims to conduct cost-effectiveness analysis of posaconazole 
(POS) compared with standard azole therapy including ﬂ uconazole (FLU) or itracon-
azole (ITR) for prophylaxis of invasive fungal infection (IFI) with netropenia in South 
Korea. METHODS: A decision tree was used to estimate the proportion of the surviv-
ing patients cohort during the 100-day period following initiation of prophylaxis. The
surviving patients in the decision tree were extrapolated to a lifetime horizon using
Markov model to estimate the incremental cost per life-year gained. Effectiveness 
parameters used in the decision tree were obtained from clinical trial. And IFI treat-
ment costs were estimated from hospital survey. The price of POS was proposed by 
the manufacturing company and calculated based on the average KRW-Euro exchange
rate of 2008. Deterministic one-way and probabilistic sensitivity analyses (PSA) were 
conducted, as well. RESULTS: Base-case analysis showed that POS resulted in a gain
of 0.092 life years (2.417 vs. 2.324) with KRW 1,457,512 of additional costs (KRW 
5,827,956 vs. 4,370,443) per patient relative to FLU or ITR. While the drug cost of 
POS was higher than that of FLU/ITR, expected IFI treatment costs were lower in
patients with POS than in patients with FLU/ITR. The incremental cost-effectiveness 
ratio was KRW 15,798,087 (€9,995) per life-year gained. PSA revealed that POS was 
cost-effective with a 50% probability at about KRW 22,000,000 (€14,000). CON-
CLUSIONS: The results of cost-effectiveness analysis showed that POS is potentially 
beneﬁ cial in IFI prophylaxis among patients with neutropenia in South Korea.
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BACKGROUND: Human papillomavirus (HPV), a precursor for cervical cancer, is 
the most common sexually transmitted infection in the United States. A quadrivalent 
vaccine (Gardasil), which was approved by the US FDA in June 2006, targets HPV 
16 and 18, which cause 70% cervical cancer, and HPV 6 and 11, which cause genital 
warts. OBJECTIVES: To evaluate the cost-effectiveness of HPV vaccine compared to 
the current screening program. The result expressed by quality-adjusted life-years
(QALYs), and incremental cost-effectiveness ratios (ICER). METHODS: A backward 
induction model was used to estimate the results. A cohort of female aged 12 to 70 
was projected. Girls are vaccinated at age 12, assuming that this vaccine is life-long 
protective, 85% efﬁ cacy, women complete 3 shots and assuming a 3% discount rate.
Model parameters were taken from published literature. Costs and QALYs were cal-
culated in 5-years intervals. One-way sensitivity analyses were conducted on critical 
or uncertain model parameters. RESULTS: HPV vaccines had both higher total costs 
($48,342) and higher QALYs (3.07 days) than girls receiving screening tests. The 
vaccine cost-effectiveness ratio was $15,749 per quality-adjusted life-year (QALY) 
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gained. Sensitivity analyses show that vaccine efﬁ cacy and whether vaccine is life-long
protective are the most inﬂ uential parameters impacting model outcomes. ICER
changed to 71.11% if the efﬁ cacy is down to 70%, 32.60% if the efﬁ cacy is 100%; 
and 200.04% if the vaccine provides only 10 year protection. CONCLUSIONS: These
results show that HPV vaccine is cost-effective compared to screening alone. Further 
studies should be done to establish more precise model parameters, such as vaccine
efﬁ cacy, duration, adverse event rates and cost for adverse events.
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OBJECTIVES: To determine whether the use of i.v. Daptomycin or i.v. Vancomycin
is the most cost-effective alternative for the treatment of infective endocarditis in public
health care institutions in Mexico METHODS: A cost-effectiveness study was per-
formed considering an institutional perspective and comparing the use of the evaluated 
alternatives as ﬁ rst-line antibiotic therapy. A systematic review was performed in order
to collect data about clinical success, length of stay at hospital services and adverse
events due to the use of either i.v. Daptomycin or i.v. Vancomycin. The use of resources 
matrix considered the selected antibiotic therapy, concomitant medication, length of 
stay at hospital services, and a second-line antibiotic therapy in case of failure. A 
decision tree with Bayesian approach was designed to simulate the use of resources.
Patient’s outcomes were supposed to be clinical success (in either short hospital stay 
or long hospital stay) and therapeutic failure which can be caused by death or lack
of efﬁ cacy of the antibiotic. Results were evaluated with incremental analysis and 
one-way sensitivity analysis of the most uncertain variables were also conducted. 
RESULTS: The use of i.v. Daptomycin results in the lowest total cost (DAP: $7,847.00 
USD; VAN:$7,990.00 USD) and the lowest cost per clinical success (CS) (DAP:
$17,754.00 USD/CS; VAN:$23,083.00 USD/CS) compared with i.v. Vancomycin. The 
sensitivity analysis varying clinical success rates of every evaluated alternative showed 
robustness of base study. CONCLUSIONS: Daptomycin is the most cost-effective
alternative in the treatment of Infective Endocarditis and MRSA Bacteremia when 
used as ﬁ rst-line antibiotic therapy, since its use reduces the length of hospital stay 
reducing expenses of public health system budget in Mexico. The use of Daptomycin
can be considered as safer when compared to use Vancomycin, because it has been 
reported less frequently event adverse in long term treatments.
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OBJECTIVES: Polymyxin B-immobilized hemoperfusion cartage (PMX) is a medical
device for the treatment of severe sepsis by adsorbing and eliminating plasma endo-
toxin. The objective of this study is to assess the clinical effectiveness and cost-
effectiveness of PMX vs. conventional therapy in treating patients with severe sepsis. 
METHODS: For a systematic review, we searched OVID, EMBASE and Cochrane 
central register of controlled trial (CENTRAL). Inclusion criteria of clinical trials were
RCTs on ‘sepsis’, ‘severe sepsis’ and ‘septic shock’ patients. We included those studies
that reported at least one of the four speciﬁ ed outcomes: mortality, plasma endotoxin
level, days of ICU stay and blood pressure. Relevant outcomes were synthesized using 
RevMan 5.0. The average medical cost of sepsis was estimated from a national health 
insurance (NHI) claims database and the PMX related cost was calculated from the 
fee schedule of NHI. For economic evaluation, we assessed incremental cost effective-
ness ratio (ICER) of PMX compared with conventional therapy. The assessment was
performed from a purchaser’s perspective. RESULTS: A total of 11 RCTs were identi-
ﬁ ed with pooled sample size of 802; 477 in PMX and 325 in conventional therapy 
group. Meta-analysis results showed that PMX therapy had signiﬁ cantly lower mortal-
ity risk. The 28-day mortality rate of PMX group and conventional therapy group
were 35.4% and 70.4% respectively with risk ratio of 0.51 (95% CI, 0.43–0.59). The
medical cost for sepsis turned out 3,536,000 KRW per patient, which is common in 
PMX and conventional treatment. The additional cost related to PMX treatment was 
estimated to be KRW5,496,984 KRW per patient. Applying this mortality outcome
and cost data, we produced an ICER of KRW15,705,669 per life gained. CONCLU-
SIONS: Compared with conventional therapy alone, PMX therapy with conventional
therapy for the treatment of severe sepsis was found clinically superior and cost-
effective as well.
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OBJECTIVES: Streptococcus pneumoniae infections in adults are associated with
substantial morbidity, mortality, and costs. The objective of this study was to provide 
an analysis of the conclusions and assumptions of published studies on the cost-
effectiveness of pneumococcal polysaccharide vaccination (PPV-23 (23 serotypes)) in
adults. METHODS: A search of recent literature (1997–2008) was conducted to 
identify cost-effectiveness studies pertaining to the use of PPV for the prevention of 
invasive pneumococcal disease (IPD) in adults. A structured review of the impact of 
model assumptions on cost-effectiveness ratios was undertaken. Cost per life year
gained (LYG) or quality adjusted life year (QALY) were reported in 2007 US dollars. 
RESULTS: The literature search identiﬁ ed 31 studies, 19 of which reported some cost
data but did not include cost–effectiveness data for PPV-23 vaccination. All but one 
of the remaining twelve studies compared PPV-23 vaccination with no vaccination, 
and these were included in this analysis. Vaccination of over 65 year olds with PPV-23 
for the prevention of IPD was found to be cost-effective with incremental cost effective-
ness ratios ranging from 2007 $9,810 to $26,160 per LYG and from $9.08 (cost-
saving) to $53,955 per QALY. Review of model parameters revealed that the results 
of these studies have to be considered in the light of limitations of available data on 
vaccine effectiveness, disease incidence, and case-fatality ratios. CONCLUSIONS: All 
the reviewed studies reported that PPV-23 is a cost-effective, and in some cases a
cost-saving, vaccination strategy for the prevention of IPD in the elderly. Further eco-
nomic evaluation of PPV-23 may be warranted based on the availability of new data 
on vaccine efﬁ cacy, IPD incidence and case fatality in the adult population in the
post-PCV-7 era.
PIN21
VARIATION IN EFFICIENCY FRONTIERS FOR HIV/AIDS
PREVENTION AND TREATMENT
Kamae M1, Kamae I2, Cohen JT1, Neumann PJ1
1Tufts-New England Medical Center, Boston, MA, USA, 2Keio University, Fujisawa, Kanagawa, 
Japan
OBJECTIVES: To investigate how the cost-effectiveness of preventing or treating 
HIV/AIDS varies by a series of potentially relevant external factors. METHODS:
We reviewed the cost-effectiveness evidence for HIV/AIDS prevention and treat-
ment in the Cost-Effectiveness (CEA) Analysis Registry at Tufts Medical Center
(www.cearegistry.org) from 2002–06, and then constructed efﬁ cient frontier curves 
(EF curve) in terms of incremental cost per QALY ratios based on extracted evidence 
using methods introduced by Institute for Quality and Efﬁ ciency in Health Care
(IQWiG), Germany. All articles that report cost-effectiveness as USD/QALYs were
selected, including information on the following factors: payer perspective; prevention 
stage; intervention type, and country of study. We excluded articles with time horizon
30 years and those without discounting. RESULTS: Of 237 eligible articles in the 
CEA Registry, we extracted 11 HIV/AIDS-related articles, which included 84 individ-
ual cost-effectiveness (CE) ratios. Plotted EF curves were visually distinct, depending
on the prevention type, with primary prevention interventions being most efﬁ cient.
With respect to country, the EF curve for the U.S. and South Africa were separate,
with the curve for South Africa lying near the vertical axis, reﬂ ecting low cost per
QALY ratios for interventions studied. Subgrouping by payer perspective (societal or 
health care payer) and intervention type (pharmaceutical, education, and screening)
did not affect the separation of the lines. CONCLUSIONS: The CE ratio clustering 
in HIV/AIDS was found on the C-E plane, which suggested separate EF curves should
be considered by stratifying by prevention stage and country. These results may differ
for other diseases, but this analysis shows that stratiﬁ ed EF analysis could help to
develop a deeper appreciation of cost-effectiveness beyond crude cost per QALY ratios
without stratiﬁ cation.
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OBJECTIVES: Vaccination of elderly and at-risk population against Streptococcus 
pneumonia is recommended and partially reimbursed in Turkey due to the substantial 
medical and economic burden. However, only ^2% of these populations were vacci-
nated in 2007. A three-step economic analysis was designed to measure the burden 
of pneumococcal infections (pneumonia and bacteremia) from a public payer perspec-
tive in elderly (60 years) and at-risk adults (18–59 years), and to evaluate the beneﬁ ts 
of implementing a vaccination program. METHODS: Firstly, we evaluated the cost 
of pneumonia and bacteremia in retrospective and prospective studies in public 
hospital services in Ankara. Secondly, a static model was used to evaluate cost-
effectiveness of vaccination in the two targeted populations using demographic and
epidemiological data obtained from Turkish sources or, when unavailable, from inter-
national literature. A stochastic Monte Carlo simulation estimated the incremental 
cost-effectiveness ratio in Euros (€) per life year gained (LYG), assuming that vaccina-
tion protected for 5 years with 50–70% effectiveness against pneumococcal bacteremia 
